Relevant case law
58 The plurality in AstraZeneca AB v Apotex Pty Ltd (2014) 226 FCR 324 at [250] briefly discussed the history of s 43(3) of the Act and its predecessor provision in the Patents Act 1952 (Cth), noting that these provisions were included to overcome the ruling in Thornhill's Application [1962] RPC 199.
59 In Thornhill's Application, consideration was given to the drafting of the following claim. It should be noted that the indices (a), (b)(i), (b)(ii), (c) and (d) were added to the claim at the hearing before the Hearing Officer in that case to illustrate the argument made. The indices did not appear in the printed specification:
1. A method of producing a black tea concentrate (a) which consists in cutting, grinding, or otherwise finely dividing fresh green leaves of the tea tree, and (b) oxidising the comminuted particles either (i) by exposing the raw mass to the action of the oxygen of the air until the mass becomes dark brown in colour and subsequently extracting by boiling water or steam the water-soluble constituents of the leaves, or (ii) initially after comminuting the leaves extracting in the same way by percolation the soluble constituents of the leaves and introducing into the obtained solution a minute quantity of an oxidising inorganic substance, (c) subjecting the solution obtained in either way to heating in the open air at a temperature approaching the boiling point of water for a duration up to six hours until the required degree of oxidation is attained and until as a result of heating there occurs the polymerisation of the tannin compounds polyphenol and catechol with constituents of the solution and the solution has lost its bitter taste inherent in the solution of the constituents of the green tea leaf, and (d) evaporating excess water.
60 The Hearing Officer described the claim as follows:
It will be noted that claim 1 embodies two alternatives, i.e. it may be regarded as two claims 1A and 1B, wherein: -
1A = a + b(i) + c + d
and the method which may be represented as
1B = a + b(ii) + c + d
61 The Hearing Officer concluded that, as the claim could be regarded as two notional claims, each notional claim could be afforded its own priority date. However, on appeal, Lloyd-Jacob J concluded (at 207) that there was no provision in the Patents Act 1949 (UK) that would warrant the attribution of two different priority dates to different parts of the one claim.
62 In AstraZeneca, one of the claims in question (claim 1 of what was called the 842 or cation patent) was as follows:
1. A pharmaceutical composition comprising [rosuvastatin] or a pharmaceutically acceptable salt thereof as the active ingredient and an inorganic salt in which the cation is multivalent, provided that:
(i) the inorganic salt is not hydrotalcite or synthetic hydrotalcite; and
(ii) the counter anion to the inorganic salt is not a phosphate.
63 At [251], the plurality concluded (Jessup J agreeing at [447]):
251 In our view, claim 1 of the 842 or cation patent does not define more than one form of the invention. Unlike the claim in issue in Thornhill's Application, claim 1 of the 842 or cation patent does not by its terms allow for any alternatives or, adopting the language of s 43(3), different forms of the same invention. Claim 1 defines only one form of the invention even though there will be any number of potential variants that are within its scope. We do not think s 43(3) is intended to treat every potential variant of the defined invention as if it was a form of the invention that must be treated as a separate claim which is to be given its own priority date. Rather, it is intended to deal with very different situations such as that which arose in Thornhill's Application or where, to take a slightly different example, a claim is dependent on one or more independent claims (claim 3 of the 842 or cation patent takes this form) each of which has a different priority date. We therefore reject AstraZeneca's submission based upon s 43(3) of the Act.
(Emphasis in original.)
64 The corresponding provision in the United Kingdom is s 125 of the Patents Act 1977 (UK). Section 125 relevantly provides:
125 Extent of invention
(1) For the purposes of this Act an invention for a patent for which an application has been made or for which a patent has been granted shall, unless the context otherwise requires, be taken to be that specified in a claim of the specification of the application or patent, as the case may be, as interpreted by the description and any drawings contained in that specification, and the extent of the protection conferred by a patent or application for a patent shall be determined accordingly.
(2) It is hereby declared for the avoidance of doubt that where more than one invention is specified in any such claim, each invention may have a different priority date under section 5 above.
…
65 In Miller R, Burkill G, Birss C and Campbell D, Terrell on the Law of Patents (17th ed, Sweet and Maxwell, 2011), the authors state (at 7-12):
When can a claim have multiple priorities?
7-12 If a claim is drafted in such a way that it encompasses clear alternatives - for example, a claim which defines a chemical compound by reference to a structure which may take identified alternative forms - then attributing multiple priorities is unlikely to cause difficulty. In effect, the claim can be regarded as being made up of several discrete claims or - in the words of section 125(2) - as specifying more than one invention, each with a different priority date. However, it is difficult to see how a broad claim which does not set out alternatives as such could be regarded as specifying more than one invention, and it is hard to see how such a claim could allow for multiple priorities to be claimed. This is in line with the approach taken by the European Patent Office.
(Citations omitted.)
66 Section 125(2) of the Patents Act 1977 (UK) was considered in Hallen Company v Brabantia (UK) Ltd [1990] FSR 134. In that case, a particular claim (claim 9) claimed "an apparatus according to any preceding claim". Aldous J construed the claim as being a number of discrete claims, and not a composite claim. At 140, Aldous J said:
The use of the words "apparatus according to any preceding claim" is a shorthand way of writing out a large number of claims. For instance, if those words are used in claim 3 of a patent having three claims, what is being claimed, and claimed separately, is the combination of claims 1 and 3 and claims 1, 2 and 3. To hold to the contrary … would mean that the patentees in the future would have to write out each combination as a separate claim which would lead to even more claims in patents than there are now.
67 In Merck & Company (Macek's) Patent [1967] RPC 157, Lloyd-Jacob J considered an allegation of prior claiming in relation to a number of claims in a granted patent, including the following:
1. A composition having enhanced bactericidal activity comprising novobiocin in combination with at least one other antibiotic selected from the following, namely, penicillin, tetracycline, oxytetracycline, chlortetracycline, streptomycin, chloramphenicol, bacitracin, neomycin, spiramycin, streptothricin and grisein.
68 As to the construction of this claim, Lloyd-Jacob J said:
The claim, it will be seen, is of the comprehensive type permitting of alternative additions to novobiocin, which alternative additions consist of one or more of the named antibiotics. It is a convenient summation of what is in effect a number of separate claims to different compositions of which some will relate to compositions having two ingredients and some to three or more ingredients.
The first notional rewriting of this claim to make plain this differentiation would be: (A) "A composition having enhanced bactericidal activity comprising novobiocin in combination with one other antibiotic selected from the following, namely, penicillin, tetracycline, oxytetracycline, chlortetracycline, streptomycin, chloramphenicol, bacitracin, neomycin, spiramycin, streptothricin and grisein." (B) "a composition . . . comprising novobiocin in combination with two or more antibiotics selected from the following, namely, penicillin, tetracycline, oxytetracycline, chlortetracycline, streptomycin, chloramphenicol, bacitracin, neomycin, spiramycin, streptothricin and grisein."
Of these two notional divisions of claim 1 only "A" is relevant and this may be notionally further rewritten in the form of eleven independent claims in the form, (C) "A composition . . . comprising novobiocin in combination with penicillin"; (D) "A composition . . . comprising novobiocin in combination with tetracycline"; (E) "A composition . . . comprising novobiocin in combination with oxytetracycline"; (F) "A composition . . . comprising novobiocin in combination with chlortetracycline"; and so on through the list.
69 Although dealing with prior claiming, Merck provides guidance on how claims of the kind there under consideration are to be construed. The applicant placed reliance on Merck because the relevant claim had drafting similarities to claims 1 and 3 of the 355 specification in that each of these claims provides an explicit selection step leading to various combinations and hence various phosphors within the scope of the claim. The applicant submitted that if the claim in Merck was written out as described by Lloyd-Jacob J, it would comprise 2,047 claims.
70 The applicant also referred to "claim splitting" cases where, in order to avoid the problem posed by Thornhill's Application, amendments were sought to split a composite claim into various forms of the invention so as to render each as a separate claim with its own priority date. Farbenfabriken Bayer AG's Patent [1966] RPC 278 and Anderson's Application [1966] FSR 218 are two such examples. It is not necessary for me to refer to these cases in greater detail.